Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Aclaris Therapeutics Inc (NASDAQ: ACRS) was $4.07 for the day, up 6.54% from the previous closing price of $3.82. In other words, the price has increased by $6.54 from its previous closing price. On the day, 1.01 million shares were traded. ACRS stock price reached its highest trading level at $4.235 during the session, while it also had its lowest trading level at $3.85.
Ratios:
Our analysis of ACRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.03 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 19, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $2 to $7.
Jefferies Upgraded its Hold to Buy on November 19, 2024, whereas the target price for the stock was revised from $2 to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Leonard Braden Michael bought 206,025 shares of ACRS for $256,357 on Aug 05 ’24. The 10% Owner now owns 14,250,000 shares after completing the transaction at $1.24 per share. On Aug 02 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 167,544 shares for $1.29 each. As a result, the insider paid 216,400 and bolstered with 14,043,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 290723744 and an Enterprise Value of 165246928. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.44 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 6.102 whereas that against EBITDA is -2.657.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 105.28%, while the 200-Day Moving Average is calculated to be 190.41%.
Shares Statistics:
ACRS traded an average of 2.17M shares per day over the past three months and 10516110 shares per day over the past ten days. A total of 70.89M shares are outstanding, with a floating share count of 63.76M. Insiders hold about 16.09% of the company’s shares, while institutions hold 75.64% stake in the company. Shares short for ACRS as of 1731628800 were 1559255 with a Short Ratio of 0.72, compared to 1728950400 on 1390952. Therefore, it implies a Short% of Shares Outstanding of 1559255 and a Short% of Float of 2.5999999.
Earnings Estimates
A comprehensive evaluation of Aclaris Therapeutics Inc (ACRS) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.6 and -$1.13 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.52, with 6.0 analysts recommending between -$0.45 and -$0.59.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $31.1M to a low estimate of $645k. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $17.57MFor the next quarter, 8 analysts are estimating revenue of $3.25M. There is a high estimate of $6.1M for the next quarter, whereas the lowest estimate is $645k.
A total of 7 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $40.6M, while the lowest revenue estimate was $10.15M, resulting in an average revenue estimate of $15.79M. In the same quarter a year ago, actual revenue was $31.25MBased on 8 analysts’ estimates, the company’s revenue will be $12.04M in the next fiscal year. The high estimate is $26.4M and the low estimate is $2.57M.
